Basile Njei, MD, PhD, MPH, FACHDM
Assistant ProfessorCards
About
Research
Publications
2024
The impact of overweight and obesity on health outcomes in the United States from 1990 to 2021.
Al Ta'ani O, Al-Ajlouni YA, Aleyadeh W, Al-Bitar F, Alsakarneh S, Saadeh A, Alhuneafat L, Njei B. The impact of overweight and obesity on health outcomes in the United States from 1990 to 2021. Diabetes Obes Metab 2024, 26: 5455-5465. PMID: 39261301, DOI: 10.1111/dom.15924.Peer-Reviewed Original ResearchThe burden of cirrhosis and other chronic liver disease in the middle east and North Africa (MENA) region over three decades.
Al Ta'ani O, Aleyadeh W, Al-Ajlouni Y, Alnimer L, Ismail A, Natour B, Njei B. The burden of cirrhosis and other chronic liver disease in the middle east and North Africa (MENA) region over three decades. BMC Public Health 2024, 24: 2979. PMID: 39468483, DOI: 10.1186/s12889-024-20445-5.Peer-Reviewed Original ResearchDiagnosis and Management of Lean Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review.
Njei B, Ameyaw P, Al-Ajlouni Y, Njei LP, Boateng S. Diagnosis and Management of Lean Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review. Cureus 2024, 16: e71451. PMID: 39544615, DOI: 10.7759/cureus.71451.Peer-Reviewed Original ResearchEfficacy and Safety of GLP-1 Receptor Agonists in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Njei B, Al-Ajlouni Y, Lemos SY, Ugwendum D, Ameyaw P, Njei LP, Boateng S. Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cureus 2024, 16: e71366. PMID: 39534801, DOI: 10.7759/cureus.71366.Peer-Reviewed Original ResearchRecipient functional status impacts on short and long-term intestinal transplant outcomes in United States adults.
Boateng S, Ameyaw P, Gyabaah S, Adjepong Y, Njei B. Recipient functional status impacts on short and long-term intestinal transplant outcomes in United States adults. World J Transplant 2024, 14: 93561. PMID: 39295973, DOI: 10.5500/wjt.v14.i3.93561.Peer-Reviewed Original ResearchSevere Acute Liver Injury After Hepatotoxic Medication Initiation in Real-World Data
Torgersen J, Mezochow A, Newcomb C, Carbonari D, Hennessy S, Rentsch C, Park L, Tate J, Bräu N, Bhattacharya D, Lim J, Mezzacappa C, Njei B, Roy J, Taddei T, Justice A, Re V. Severe Acute Liver Injury After Hepatotoxic Medication Initiation in Real-World Data. JAMA Internal Medicine 2024, 184: 943-952. PMID: 38913369, PMCID: PMC11197444, DOI: 10.1001/jamainternmed.2024.1836.Peer-Reviewed Original ResearchIncidence rateUS Department of Veterans AffairsMedication initiationDepartment of Veterans AffairsInitiation of medicationVeterans AffairsMain OutcomesPotential of medicationsOutpatient settingDischarge diagnosisCohort studyDay of admissionCase reportReal World DataReport countsMedicationMedical cohortSevere acute liver injuryUS DepartmentFollow-upAcute liver injuryHospitalCohortHepatotoxic medicationsIncidenceImpact of Recipient and Donor Body Mass Index on Survival Outcomes After Intestinal Transplantation: A United Network for Organ Sharing Database Analysis.
Ameyaw PA, Boateng S, Annor EN, Njei B. Impact of Recipient and Donor Body Mass Index on Survival Outcomes After Intestinal Transplantation: A United Network for Organ Sharing Database Analysis. Ann Transplant 2024, 29: e943994. PMID: 38978263, DOI: 10.12659/AOT.943994.Peer-Reviewed Original ResearchAssociation of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) With an Increased Risk of Congestive Heart Failure in Hospitalized Patients With Cirrhosis: A Propensity Score-Matched Analysis.
Ugwendum D, Mohamed M, Al-Ajlouni YA, Nso N, Njei B. Association of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) With an Increased Risk of Congestive Heart Failure in Hospitalized Patients With Cirrhosis: A Propensity Score-Matched Analysis. Cureus 2024, 16: e62441. PMID: 39011212, DOI: 10.7759/cureus.62441.Peer-Reviewed Original ResearchCost-effectiveness analysis: The missing factor in the management of HCC
Njei B, Yi I, Strazzabosco M. Cost-effectiveness analysis: The missing factor in the management of HCC. Clinical Liver Disease 2024, 23: e0178. PMID: 38860130, PMCID: PMC11164007, DOI: 10.1097/cld.0000000000000178.Peer-Reviewed Original ResearchMortality, Hepatic Decompensation, and Cardiovascular- and Renal-Related Outcomes in Lean Versus Non-lean Patients Hospitalized With Metabolic Dysfunction-Associated Steatohepatitis (MASH).
Ezeani C, Omaliko C, Al-Ajlouni YA, Njei B. Mortality, Hepatic Decompensation, and Cardiovascular- and Renal-Related Outcomes in Lean Versus Non-lean Patients Hospitalized With Metabolic Dysfunction-Associated Steatohepatitis (MASH). Cureus 2024, 16: e60968. PMID: 38915982, DOI: 10.7759/cureus.60968.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
News
News
- December 03, 2024Source: MEDPAGETODAY
Lean MASH Patients Face Higher Mortality and Worse Outcomes
- October 27, 2024Source: HCPLive American College of Gastroenterology
Basile Njei, MD, MPH, PhD: Increasing Lean MASLD Awareness, Improving Screening
- October 04, 2024
Voices of DEI: Basile Njei, MD, MPH, PhD
- June 05, 2023
Welcome New Faculty and Staff in the Section of Digestive Diseases (May 2023)